FDA Approves First Biosimilar of Natalizumab for the Treatment of Relapsing Multiple Sclerosis
The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.
Source: pharmacytimes.com
Polpharma Biologic News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Polpharma Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Polpharma Biologic Today - Breaking & Trending Today
Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights
/PRNewswire/ -- According to Biogen's earnings call on Wednesday, February 15, 2023, sales for its multiple sclerosis (MS) franchise are down for the third...
Source: prnewswire.com